EIK 1003
Alternative Names: EIK-1003; IMP-1734Latest Information Update: 17 Sep 2025
At a glance
- Originator IMPACT Therapeutics
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 30 May 2025 Efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 23 Oct 2024 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical study in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 11 Dec 2023 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06253130)